Wenju Lu

Wenju Lu

Auto-generated profile, based on publicly available information

Wenju Lu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Redox Biology
Verified
Journal Article
Open access
RGRuijuan Guan
Ruijuan Guan
JWJian Wang
Jian Wang
ZCZhou Cai
Zhou Cai
ZLZiying Li
Ziying Li
LWLan Wang
Lan Wang
WLWenju Lu
Wenju Lu
Airway remodeling is one of the characteristics for chronic obstructive pulmonary disease (COPD). The mechanism underlying airway remodeling is associated with epithelial-mesenchymal transition (EMT) in the small airways of smokers and patients with COPD. Sirtuin 1 (SIRT1) is able to reduce oxidative stress, and to modulate EMT. Here, we investigated the effects and mechanisms of hydrogen sulfide (H2S) on pulmonary EMT in vitro and in vivo. We found that H2S donor NaHS inhibited cigarette smoke (CS)-induced airway remodeling, EMT and collagen deposition in mouse lungs. In human bronchial epithelial 16HBE cells, NaHS treatment also reduced CS extract (CSE)-induced EMT, collagen deposition and oxidative stress. Mechanistically, NaHS upregulated SIRT1 expression, but inhibited activation of TGF-β1/Smad3 signaling in vivo and in vitro. SIRT1 inhibition by a specific inhibitor EX527 significantly attenuated or abolished the ability of NaHS to reverse the CSE-induced oxidative stress. SIRT1 inhibition also abolished the protection of NaHS against CSE-induced EMT. Moreover, SIRT1 activation attenuated CSE-induced EMT by modifying TGF-β1-mediated Smad3 transactivation. In conclusion, H2S prevented CS-induced airway remodeling in mice by reversing oxidative stress and EMT, which was partially ameliorated by SIRT1 activation. These findings suggest that H2S may have therapeutic potential for the prevention and treatment of COPD.

1 April 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
RGRuijuan Guan
Ruijuan Guan
JWJian Wang
Jian Wang
DLDefu Li
Defu Li
ZLZiying Li
Ziying Li
HLHanwei Liu
Hanwei Liu
WLWenju Lu
Wenju Lu

3 June 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
YLyuanyuan Li
yuanyuan Li
WQWenguang Qin
Wenguang Qin
QLQiuling Liang
Qiuling Liang
JZJiamin Zeng
Jiamin Zeng
QYQiong Yang
Qiong Yang
WLWenju Lu
Wenju Lu
Bufei huoxue (BFHX) is a Traditional Chinese Medicine formulation that consists of Astragalus Exscapus L, Paeonia Lactiflora Pall, and Psoralea Aphylla L. It can ameliorate collagen deposition and inhibit EMT. However, it remains unknown whether and how BFHX alleviates IPF. Our work aimed to explore the therapeutic efficacy of BFHX on IPF and dissect the mechanisms involved. A mouse model of IPF was induced by bleomycin. BFHX was administered on the first day of modeling and maintained for 21 days. Pulmonary fibrosis and inflammation were evaluated by micro-CT, lung histopathology, pulmonary function assessment, and cytokines in BALF. In addition, we examined the signaling molecules involved in EMT and ECM by immunofluorescence, western Blot, EdU, and MMP (Δψm) assays. BFHX alleviated lung parenchyma fibrosis as evidenced by Hematoxylin-eosin (H&E), Masson's trichrome staining, and micro-CT, and it improved lung function. In addition, BFHX treatment not only decreased the levels of interleukin (IL)-6 and tumor necrosis factor-α (TNF-α), but also upregulated E-cadherin (E-Cad) and downregulated α-smooth muscle actin (α-SMA), collagen Ӏ (Col Ӏ), vimentin, and fibronectin (FN). Mechanistically, BFHX repressed TGF-β1-driven Smad2/3 phosphorylation, which, in turn, suppressed EMT and transition of fibroblasts to myofibroblasts in vivo and in vitro. BFHX effectively reduces the occurrence of EMT and inhibits the production of ECM by inhibiting the TGF-β1/Smad2/3 signaling pathway, which provides a potential novel therapeutic strategy for IPF.

1 April 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
DLDefu Li
Defu Li
DSDejun Sun
Dejun Sun
LYLiang Yuan
Liang Yuan
CLChunli Liu
Chunli Liu
LCLingzhu Chen
Lingzhu Chen
WLWenju Lu
Wenju Lu

1 December 2019 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
LZLi-Bo Zhou
Li-Bo Zhou
YZYao-Ming Zheng
Yao-Ming Zheng
WLWen-Jing Liao
Wen-Jing Liao
LSLi-Juan Song
Li-Juan Song
XMXuan Meng
Xuan Meng
XZXiaowen ZHANG
Xiaowen ZHANG

10 January 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
ZZZili Zhang
Zili Zhang
FLFanjie Lin
Fanjie Lin
FLFei Liu
Fei Liu
QLQiongqiong Li
Qiongqiong Li
YLYuanyuan Li
Yuanyuan Li
WLWenju Lu
Wenju Lu
The mortality rate for critically ill COVID-19 cases was more than 80%. Nonetheless, research about the effect of common respiratory diseases on critically ill COVID-19 expression and outcomes is scarce. We performed proteomic analyses on airway mucus obtained by bronchoscopy from patients with severe COVID-19, or induced sputum from patients with chronic obstructive pulmonary disease (COPD), asthma, and healthy controls. Of the total identified and quantified proteins, 445 differentially expressed proteins (DEPs) were found in different comparison groups. In comparison with COPD, asthma, and controls, 11 proteins were uniquely present in COVID-19 patients. Apart from DEPs associated with COPD versus controls and asthma versus controls, there was a total of 59 DEPs specific to COVID-19 patients. Finally, the findings revealed that there were 8 overlapping proteins in COVID-19 patients, including C9, FGB, FGG, PRTN3, HBB, HBA1, IGLV3-19, and COTL1. Functional analyses revealed that most of them were associated with complement and coagulation cascades, platelet activation, or iron metabolism, and anemia-related pathways. This study provides fundamental data for identifying COVID-19–specific proteomic changes in comparison with COPD and asthma, which may suggest molecular targets for specialized therapy.